Delivery Devices and Therapeutics to the Ear

Dr. Stephen J. McCormack
President and CEO, NeuroSystec

June 1, 2005
CLU - Richter Hall Ahmanson Science Building

The FDA has just approved RFID (Radio Frequency Identification) technology for medical use in humans. RFID an innovative solution that opens the door for an immense set of opportunities, such as recording patient ID, patient's condition and safety, record of past treatments, important medical conditions that need to be known by healthcare staff, but also integrated medication management. The hospital setting also is a fertile ground for RFID with asset management, and inventory control.

This talk will introduce the concept and scope of RFID, present its potential for the healthcare/medical industry, share the wisdom and lessons learned from its use in other industry, and will leave the audience with an interesting perspective on the impacts of RFID in the humanity's ability to manage its health. RFID is now also being introduced in the pharmaceutical industry - current and potential applications of which will be discussed.

Dr. Stephen J. McCormack

Dr. Stephen J. McCormack has more than 18 years experience in the biopharmaceutical industry, from fundamental research and technology development to intellectual property and commercialization of therapeutics. Dr. McCormack co-founded NeuroSystec for the development of therapeutics to treat neurological diseases. Prior to NeuroSystec he founded AlleCure who he merged with two other biotechnology companies to form MannKind Corporation. Previously, Dr. McCormack was part of the founding senior management at the Keck Graduate Institute. He has held academic positions at George Mason University, Georgetown University Medical Center, Rockefeller University and the University of Massachusetts Medical Center. 
Dr. McCormack's scientific contributions include developing diagnostic screens for breast and cervical cancer and he has made several seminal discoveries that resulted in improved medical therapies. He has published numerous research papers, book chapters and abstracts, and has submitted multiple patent applications. Among many honors, he earned the National Cancer Institute's National Research Service Award and National Institutes of Health SPORE Fellowship while at Georgetown University. He also received the International Society for Interferon Research Award and University of California Academic Senate Award. He is currently an affiliate faculty member of the Kennedy Institute of Ethics at Georgetown University and is actively involved in public policy issues related to commercialization and patenting in the biopharmaceutical industry. Dr. McCormack received his PhD in the interdepartmental Biomolecular Science and Engineering program from University of California, Santa Barbara. He obtained a bachelor’s degree in biology from the College of the Holy Cross in Worcester, MA. He also completed the Advanced Management Program at Harvard Business School in Cambridge, MA.